VistaGen Therapeutics(VTGN) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Vistagen Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update Fasedienol U.S. registration-directed PALISADE Phase 3 Program for acute treatment of social anxiety disorder progressing PALISADE-3 and PALISADE-4 Phase 3 trials initiated and underway SOUTH SAN FRANCISCO, Calif. — (BUSINESS WIRE) — November 7, 2024 — Vistagen(Nasdaq: VTGN), a late clinicalstage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today reported finan ...